Anavex Life Sciences Corp (AVXL)

[falconer66a]

Give Zen My Regards.

Sounds pretty Zen to me.

Well, I actually don't know this Zen guy. He must have things altogether.

But I do know cellular biology rather deeply, as good as any first-year med school student (well, probably better). I had to teach it to talented advanced-placement biology students enrolled in my classes specifically to gain admission and scholarships to pre-med and other advanced biology college curricula.

It's the demonstrated, tested Anavex science that directed my investment in an AVXL position. Most are not able to adequately understand the unique, facilitating details of the mechanisms of action (MOAs) and how they produce both the demonstrated and anticipated clinical results against, of all things, recalcitrant central nervous system (CNS) diseases.

What? This biotech startup thinks it can actually treat either Alzheimer's or Parkinson's disease? Get real. For Alzheimer's, they aren't even targeting either the beta-amyloids or tau plaques. The entire medical world knows that the only way to solve Alzheimer's is to chemically force the body to remove those waste proteins. Anavex, however, claims that by allowing its small molecule to stick to a little-know protein, the sigma-1 receptor, all sorts of consequent good things happen in neurons.

Today, I'm a scientist in university research program. Professionally, today I specialize in a particular sort of plant ecology, where I and my research team are implementing (with a federal grant) a new habitat clean-up protocol that I devised. Too detailed (and irrelevant) to describe here. But as a research biologist I always want to understand the biology back-story of new ideas or concepts. When I learned of Anavex I wanted to see if there was anything to what they were claiming. At the start, sure seemed bogus.

If you didn't know or understand cellular physiology or related morphology, the Anavex science makes no sense. But when I read the journal article papers on the Anavex drugs acting in animal models of human CNS diseases, I understood. Nothing bogus at all. New, previously unknown cellular chemistry, all connected to the sigma-1 receptor protein and its various cell-keeping functions. Great stuff, eventually to be commonly recognized when the FDA approves blarcamesine for clinical uses, sometime late this year or in 2023. I'll patiently wait.